Eli Lilly's Mounjaro UK Price Hike: What Actually Changed and What It Means for You

What happened in September 2025, the numbers as reported

You've searched this because a price you saw last year, or quoted to a friend, no longer matches what you're finding now. That gap is real. Eli Lilly raised Mounjaro's UK list price on 1 September 2025 (as widely reported at the time) with the sharpest movement at the higher doses. The highest-dose pen rose from around £122 to around £330 at list, and private market prices since then have typically ranged from roughly £149 to £375 a month depending on the dose and the provider. Those figures are hedged deliberately: Mounjaro is a tirzepatide medicine titrated from 2.5mg upward, so the dose you're on determines the cost. Starting-dose pricing and maintenance-dose pricing are different things, and any quote that doesn't make that distinction clearly is worth scrutinising.

For more detail on how private prices break down across the dose range, our Mounjaro prices page maps the market context by strength. If you want to understand what triggered the shift and how far prices moved at each dose, our page on the Lilly Mounjaro price covers the full picture. The broader story of why list prices moved and what that means for supply is covered on our page on the Lilly price increase in the UK.

What a headline price often leaves out, a question our prescribers hear most weeks

"I found it cheaper somewhere else" is something the clinical team hears regularly. The follow-up question is always the same: what did that price include? Private Mounjaro quotes vary not just because providers set different margins, but because they bundle very different things. Some prices cover treatment only, no consultation, no prescription fee, no delivery, no aftercare if something concerns you after your first injection. A £149 quote and a £249 quote may or may not represent the same thing, and the gap often closes once you add what the first quote excluded.

Specifically, watch for: consultation fees charged separately; prescription fees added at checkout; delivery costs (next-day tracked isn't always included); dose-review charges each time your prescriber needs to assess whether to increase; and aftercare that's email-only or on a 48-hour response window. None of these are hidden in small print by accident, they're how providers keep a headline number attractive. If you're trying to make sense of why quotes shifted so sharply, our breakdown of the Mounjaro price hike explains what changed and when. For a longer look at monthly costs versus what's actually delivered, this breakdown of what Mounjaro costs per month is worth reading before you compare quotes.

Where nume sits in this market, and why we're transparent about it

We're not the cheapest option, and we haven't tried to be. The price increase from Lilly put pressure on every private provider's margin, and some responded by narrowing what's included to hold a headline number. We responded by keeping everything in one figure: the consultation, the prescription, the treatment, next-working-day DPD delivery, and seven-day-a-week aftercare from the same clinical team that assessed you. No subscription. Every repeat order is clinically re-reviewed before it ships.

What that buys in practice: you order before 12pm on a working day, a GPhC-registered Independent Prescriber reviews your consultation personally that day, and (if clinically approved) your pen is dispatched the same afternoon. You can verify our pharmacy on the GPhC register at registration number 9012878. The current treatment pricing is shown on the consultation and treatment page; we don't print per-pen prices in body copy because the right dose for you is a clinical decision, not a catalogue choice. If you want to understand what drives our clinical approach, our lead prescriber's profile sets that out.

Why price is the wrong starting point for a prescription medicine

The MHRA has been clear: GLP-1 medicines are not assessed or appropriate for quick or cosmetic weight loss, and they're prescription-only for good reasons. Since Lilly's September 2025 price change, enforcement activity has intensified. Around 20 million doses of illegally traded weight-loss medicines (roughly £45m street value) were seized in 2025 alone, and the first illicit UK site manufacturing counterfeit tirzepatide pens was raided in Northampton in October 2025. Fake pens have contained insulin in previous cases. The pattern is consistent: prices significantly below market, sellers on social media, no clinical assessment required. A low price from an unverifiable source is a specific warning sign, not a bargain.

The right question isn't which provider is cheapest, it's which provider you can verify on the GPhC register, which uses a licensed UK supply chain, and which has a prescriber who will actually review your health before and during treatment. For a fuller read on Mounjaro as a medicine (how tirzepatide works, what the clinical trials showed, and how the NHS phased rollout interacts with private access) our Mounjaro treatment page covers the ground. And if you're ready to find out whether treatment is clinically appropriate for you, check your eligibility with a free consultation.